Entrada Therapeutics (TRDA) Non Operating Income (2020 - 2026)

Entrada Therapeutics' Non Operating Income history runs 7 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 40.91% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $13.3 million (down 32.72% YoY), while the FY2025 annual figure was $15.1 million, down 22.6% from the prior year.
• Non Operating Income was $2.6 million for Q1 2026 at Entrada Therapeutics, down from $3.1 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $5.8 million in Q3 2024 to a low of $403000.0 in Q2 2022.
• Historically, Non Operating Income has averaged $3.2 million across 5 years, with a median of $3.9 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Non Operating Income soared 7207.69% in 2022, then tumbled 40.91% in 2026.
• A 5-year view of Non Operating Income shows it stood at $950000.0 in 2022, then jumped by 351.79% to $4.3 million in 2023, then advanced by 19.48% to $5.1 million in 2024, then slumped by 38.85% to $3.1 million in 2025, then fell by 16.33% to $2.6 million in 2026.
• The last three Non Operating Income figures came in at $2.6 million (Q1 2026), $3.1 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.